ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

3:00PM-3:50PM: Abstract Number: 2036

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

3:00PM-3:50PM: Abstract Number: 1977

Delivering Fracture Prevention Through Telemedicine: A Process Evaluation

Osteoporosis & Metabolic Bone Disease (1973–1977)

3:00PM-3:50PM: Abstract Number: 1950

Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis

Cytokines & Cell Trafficking (1948–1952)

3:00PM-3:50PM: Abstract Number: 2035

Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design

Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

3:00PM-3:50PM: Abstract Number: 2037

Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts

Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

3:00PM-3:50PM: Abstract Number: 1976

High Disease Activity Is Associated with Incident Osteoporotic Fractures Among Veterans with Rheumatoid Arthritis

Osteoporosis & Metabolic Bone Disease (1973–1977)

3:00PM-3:50PM: Abstract Number: 1999

Hydroxychloroquine Is Not Cardiotoxic in Patients with Rheumatoid Arthritis

RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

3:00PM-3:50PM: Abstract Number: 1948

Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes

Cytokines & Cell Trafficking (1948–1952)

3:00PM-3:50PM: Abstract Number: 2002

Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib

RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

3:00PM-3:50PM: Abstract Number: 2033

Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

3:00PM-3:50PM: Abstract Number: 1951

Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus

Cytokines & Cell Trafficking (1948–1952)

3:00PM-3:50PM: Abstract Number: 1975

Predicting Bone Mineral Density of Lumbar Vertebrae by Assessing Plain Film with Deep Learning

Osteoporosis & Metabolic Bone Disease (1973–1977)

3:00PM-3:50PM: Abstract Number: 2034

Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics

Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

3:00PM-3:50PM: Abstract Number: 2000

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine

RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

3:00PM-3:50PM: Abstract Number: 1998

Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis

RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].